ADAC predicts downturn after strong second quarter
This article was originally published in Clinica
Executive Summary
Nuclear medicine company ADAC Laboratories has reported strong revenue growth in its second quarter, but predicts a sharp drop for the third quarter as the effects of more stringent revenue recognition policies are felt. ADAC is continuing to search for a new CFO, after the interim appointment of Robert Bunje to replace Andre Simone (see Clinica No 860, p 11).